Triple Antiplatelet Therapy with Cilostazol and Favorable Early Clinical Outcomes after Acute Myocardial Infarction Compared to Dual Antiplatelet Therapy with Standard or Potent P2Y12 Inhibitors

Current guidelines for the management of acute myocardial infarction (AMI) recommend potent P2Y12 inhibitors rather than clopidogrel to prevent ischemic events. However, their ischemic benefits are offset by an increased major bleeding risk. We compared the efficacy and safety of triple antiplatelet...

Descripción completa

Detalles Bibliográficos
Autores principales: Byun, Sungwook, Lee, Su Nam, Lim, Sungmin, Choo, Eun Ho, Choi, Ik Jun, Kim, Chan Joon, Moon, Donggyu, Park, Mahn-Won, Park, Chul Soo, Ahn, Youngkeun, Jeong, Myung-Ho, Chang, Kiyuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693255/
https://www.ncbi.nlm.nih.gov/pubmed/36431333
http://dx.doi.org/10.3390/jcm11226856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693255/
https://www.ncbi.nlm.nih.gov/pubmed/36431333
http://dx.doi.org/10.3390/jcm11226856

Ejemplares similares